In PPMS, the symptoms typically worsen steadily over time and physical and/or cognitive disability accumulates. This represents about 10-15% of people with MS. Patients are often understandably ...

Vidofludimus calcium reduced the risk of 24-week confirmed disability worsening and slowed brain shrinkage in people with ...

Overall, patient baseline characteristics were well balanced between the masitinib and placebo groups (Table 1), as well as between the PPMS and rfSPMS subpopulations (data not shown). The mean ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

In support, the evidence of focal inflammatory disease (gadolinium-enhancing lesions at baseline in 6.8% of naSPMS and 17.8% of PPMS patients) and the number of on-study relapses (5.8% in the ...

Early treatment with Ocrevus may help protect the cerebellum from damage in people with multiple sclerosis, a study found.

But after agreeing a new confidential pricing deal with Roche, NICE has recommended it for PPMS patients in England. However it will be restricted to those with early inflammatory disease ...

It is also the first drug approved for patients with primary progressive MS (PPMS), where symptoms get worse over time. In an interview with pharmaphorum, Marius Scholtz, country medical lead for ...

Recent research shows that one out of every four PPMS patients in Russia get their diagnosis confirmed only after living with the disease for several years. Without a proper diagnosis and available ...

Moreover, this positive action was observed in patients with PPMS and rfSPMS, subpopulations for whom there are practically no currently available treatments. Taken together with positive results ...